Trial Profile
Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms CLEVER
- Sponsors GWT-TUD GmbH
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 According to European Clinical Trials Database record, this trial is completed in Germany.
- 08 Oct 2019 Planned End Date changed from 1 Jan 2019 to 1 Oct 2019.